Zimmer Biomet Holdings, Inc. (ZBH): Business Model Canvas [Dec-2025 Updated]

You're digging into the mechanics of a major med-tech player, trying to see how Zimmer Biomet Holdings, Inc. is actually making its money in late 2025. Honestly, the story isn't just about selling hips and knees anymore; it's a calculated pivot toward digital surgery and disciplined acquisitions, like snapping up Monogram Technologies. They're backing this strategy with real traction, seeing U.S. organic growth hit 5.6% in Q3 and projecting full-year revenue growth between 6.7% and 7.7%, largely driven by tech like the ROSA robotics platform and their cementless Persona OsseoTi implants capturing almost 30% of the U.S. knee market, all while sitting on about $1.3 billion in cash as of Q3. Let's break down the nine blocks of their Business Model Canvas to see exactly how they're structuring this growth engine-you'll see the strategic moves behind those impressive numbers below.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Key Partnerships

You're looking at the core relationships Zimmer Biomet Holdings, Inc. (ZBH) solidified or strengthened through late 2025 to drive its strategic growth, especially in robotics and site-of-care expansion. These aren't just handshake agreements; they involve significant capital deployment and future revenue projections.

The partnership with CBRE Group, Inc. (NYSE: CBRE) is central to accelerating the shift of orthopedic procedures to the Ambulatory Surgery Center (ASC) setting. CBRE, which brings real estate expertise with over $30 billion in annual revenue and more than 100,000 professionals, combines with Zimmer Biomet Holdings, Inc.'s technology to offer a comprehensive, turnkey development solution for new and retrofitted orthopedic ASCs in the U.S.. This effort supports Zimmer Biomet Holdings, Inc.'s long-range plan targeting mid-single-digit percentage constant currency consolidated revenue Compound Annual Growth Rate (CAGR) through 2027, building on the more than $7 billion 2023 Orthopedics ASC market.

The acquisition of Monogram Technologies Inc. in July 2025 is a major commitment to autonomous robotics, integrating its technology into the ROSA Robotics platform. Here are the key financial terms of that partnership transition:

Managing the supply chain remains critical, especially given the tariff environment impacting 2025 profitability. Zimmer Biomet Holdings, Inc.'s initial forecast for the tariff headwind to operating profit in 2025 was $60 million to $80 million. However, by August 2025, mitigation efforts and lower-than-expected rates revised this estimate down to about $40 million. This revision helped lead to an increased FY 2025 adjusted EPS guidance range of $8.10 to $8.30, up from the prior range of $7.90 to $8.10. The company is actively examining sourcing changes, such as shifting from China to Europe for certain components.

Collaboration with research institutions and clinical partners underpins the pipeline, which is showing results in the latest reporting period. Zimmer Biomet Holdings, Inc.'s Q3 2025 results highlighted strong adoption of new products, contributing to:

• Third quarter net sales of $2.001 billion.
• Organic revenue growth of 5.6% in the critical U.S. business.
• Adjusted diluted earnings per share of $1.90, a 9.2% increase year-over-year.
• FDA clearance received on November 14, 2025, for an enhanced ROSA Knee Robotic Technology version.

These partnerships are designed to support the delivery of new technologies, including the world's first orthopedic implant with Iodine Technology, which received FDA Breakthrough Designation in October 2025. Finance: draft 13-week cash view by Friday.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Key Activities

You're looking at the core engine of Zimmer Biomet Holdings, Inc. (ZBH) right now, which is heavily weighted toward innovation and integrating recent, strategic moves. The operational tempo is high, especially following the Q3 2025 results.

The commitment to innovation is quantified by the forward-looking goal to launch north of 50 meaningful new products over a 36-month period, targeting markets growing above 4%, as stated in January 2025.

Manufacturing and global distribution are the backbone supporting this pipeline. For the third quarter ended September 30, 2025, Zimmer Biomet Holdings, Inc. reported net sales of $2.001 billion, which was a 9.7% increase on a reported basis. That quarter, the core Hips and Knees units generated combined sales of $1.30 billion, while the Sports Medicine, Extremities and Trauma (S.E.T.) unit brought in $541.5 million. Research and development spending for that same quarter was $115.9 million.

Here's a quick look at the scale of the Q3 2025 operational performance:

The integration of recent acquisitions is a massive key activity. Zimmer Biomet Holdings, Inc. completed the acquisition of Paragon 28 on April 21, 2025, where Paragon 28 shareholders received $13.00 in cash per share plus a contingent value right (CVR) up to $1.00 per share. Then, the Monogram Technologies acquisition closed on October 7, 2025, with an upfront cash payment of $4.04 per share plus a CVR up to $12.37 per share.

The Monogram deal is critical for robotics. Its CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology received FDA 510(k) clearance in March 2025. Management projects this acquisition will be neutral to adjusted earnings per share in 2025 through 2027, becoming accretive in 2028 and beyond.

Commercial execution is measured directly by market penetration and regional performance. You saw the U.S. business anchor the quarter, delivering 5.6% organic revenue growth in Q3 2025. That's a significant sequential acceleration from the 2.3% growth seen in the second quarter of 2025. This success is tied to specific product adoption:

• Persona OsseoTi now accounts for nearly 30% of U.S. total knee implants.
• The goal is to reach 50% penetration for Persona OsseoTi by the end of 2027.
• U.S. technology and data, bone cement, and surgical sales grew by 20.3% in the quarter.

Still, commercial execution faced headwinds, as weakness in Latin America and Emerging Markets in Europe offset some of the domestic gains, leading to a cut in the full-year organic growth guidance.

Finance: draft 13-week cash view by Friday.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Key Resources

You're looking at the core assets Zimmer Biomet Holdings, Inc. relies on to compete in the orthopedic space as of late 2025. These aren't just things they own; they are the engines driving their value proposition.

Extensive portfolio of orthopedic patents and intellectual property.

Intellectual property is the bedrock here, protecting their innovations from competitors. While I can't give you the exact count of granted patents right now, the focus is clearly on maintaining a strong defensive and offensive IP position. This is critical because losing patent protection could lead to significant sales reductions or cost increases, as noted in their filings. You see this IP muscle flexing through their latest product launches, like the Z1™ Triple-Taper Femoral Hip System, which was a highlight at the 2025 American Academy of Orthopaedic Surgeons (AAOS) meeting. It's about owning the next generation of surgical techniques.

Global manufacturing and supply chain network, including tariff mitigation efforts.

Operating globally means managing complex logistics and geopolitical risks, like tariffs. Zimmer Biomet Holdings, Inc. has been actively managing the tariff situation imposed by the Trump administration. They initially anticipated a drag on 2025 operating profits between $60 million and $80 million due to these tariffs. However, thanks to what they called successful mitigation efforts-specifically supply chain diversification and cutting back on China-based manufacturing-they revised the expected headwind down to just $40 million for the full year 2025. Also, they initiated a new global restructuring program in February 2025, expecting total pre-tax charges of approximately $85 million, with full benefits tied to completing the closure of one manufacturing facility expected within 2025.

Here's a quick look at some of the financial levers related to operations and restructuring:

ROSA surgical robotics platform and integrated digital technologies.

The ROSA platform is definitely a centerpiece of their high-tech resource base. Adoption remains strong, and they've been pushing the envelope with clearances. For instance, in November 2025, the U.S. FDA granted 510(k) clearance for the ROSA® Knee with OptimiZe™. This enhanced system is designed to integrate with ZBEdge® Analytics, letting surgeons use data for intra-operative decisions. That integration of robotics and data analytics is key to differentiating their premium offering. They were already leading the robotic-assisted neurosurgery system market globally in 2024. Plus, back in March 2025, management signaled plans to launch three additional ROSA indications within the following 18 months.

The digital and robotic assets include:

• ROSA® Knee with OptimiZe™ (FDA cleared November 2025).
• Integration with ZBEdge® Analytics for data-driven surgical decisions.
• A stated plan to launch 3 new ROSA indications by mid-2026.
• The ROSA® ONE Brain system for neurosurgery applications.

Cash and cash equivalents of approximately $1.3 billion as of Q3 2025.

Liquidity is always a primary resource, and Zimmer Biomet Holdings, Inc. reported a solid position coming out of the third quarter. As of September 30, 2025, their cash and cash equivalents stood at $1,292.7 million. That's right around the $1.3 billion mark you mentioned. This strong cash position supports their strategy of disciplined Mergers & Acquisitions (M&A), like the recent $1.2 billion acquisition of Paragon 28 in April 2025 and the $177 million acquisition of Monogram Technologies in July 2025.

Here's the balance sheet snapshot for that key resource:

Finance: draft 13-week cash view by Friday.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Value Propositions

You're looking at the core value Zimmer Biomet Holdings, Inc. (ZBH) delivers to surgeons and patients as of late 2025. It's all about a deep, comprehensive offering supported by targeted, first-to-world technology.

Comprehensive Portfolio Across Hips, Knees, and S.E.T.

Zimmer Biomet Holdings, Inc. supports a wide range of musculoskeletal needs through its core segments. The momentum in the U.S. business is clear, anchored by these product lines. For instance, in the second quarter of 2025, the combined sales from the Hips and Knees units reached $1.36 billion. Also, the S.E.T. (Sports Medicine, Extremities, and Trauma) unit showed strong acceleration, with sales climbing 17.3% to $550.6 million in that same quarter. Overall, the company reported third quarter 2025 net sales of $2.001 billion, which was a 9.7% increase on a reported basis. The critical U.S. business specifically anchored this performance with 5.6% organic revenue growth in the third quarter. I think you'll find this breadth of offering a significant differentiator.

Here's a quick look at the recent segment performance:

New-to-the-World Anti-Infective Implants

Zimmer Biomet Holdings, Inc. is delivering a first-in-class solution to combat one of orthopedics' toughest problems: Periprosthetic Joint Infections (PJI). The iodine-treated total hip replacement system is designed to inhibit bacterial adhesion. This innovation secured PMDA approval in Japan in September 2025 and subsequently received the U.S. Food and Drug Administration (FDA) Breakthrough Device Designation on October 28, 2025. To put the importance of this in perspective, PJI is estimated to occur in 1% to 2% of primary Total Joint Arthroplasties (TJA), and the associated five-year mortality rate approaches 11%, which is comparable to breast cancer. This technology directly addresses a high-consequence complication.

Advanced Robotic and Digital Surgery Solutions

The company is pushing the envelope in surgical precision and efficiency through robotics. The enhanced ROSA Knee System with OptimiZe received U.S. FDA 510(k) clearance in November 2025. This system offers customized intelligent surgical planning, where the proprietary OptimiZe Planning algorithm can reduce planning time by an average of 46%. The adoption of this technology in the U.S. is accelerating; in the third quarter of 2025, U.S. ROSA accounts performed over half of all knee implants robotically, marking an increase of 400 bps year to date. That's a significant shift in procedural preference in a single quarter.

Key robotic performance indicators include:

• FDA 510(k) clearance for ROSA Knee with OptimiZe in November 2025.
• Planning time reduction of up to 46% with OptimiZe Planning.
• U.S. robotic knee implant penetration exceeding 50% in Q3 2025.
• Year-to-date robotic penetration growth of 400 bps in Q3 2025.

Cementless Implant Technology

Zimmer Biomet Holdings, Inc. offers advanced fixation options, particularly in cementless technology, which is increasingly preferred by surgeons. The success of the Persona line is evident in market share data. In the second quarter of 2025, the Persona revision system held just over 22% of the U.S. knee reconstruction market share. This is a strong position, edging out the closest competitor's main product at just over 21% for the same period. The company has also secured clearance for components like the Persona SoluTion PPS femur, which, when combined with the Persona OsseoTi tibia and patella, offers surgeons a fully cementless alternative. The Persona OsseoTi itself features a 3D printed structure mimicking cancellous bone architecture for biological fixation.

The competitive landscape in the U.S. knee reconstruction market for Q2 2025 looked like this:

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Customer Relationships

You're looking at how Zimmer Biomet Holdings, Inc. (ZBH) maintains its critical connections with surgeons and health systems as of late 2025. It's a high-touch game in orthopedics, so the relationship strategy is central to their revenue generation.

High-touch, direct sales force model with specialized representatives.

Zimmer Biomet Holdings, Inc. leans heavily on its direct sales force to forge deep relationships with orthopedic surgeons and hospitals. This direct interaction is absolutely crucial because the devices they sell, especially the complex ones, demand specialized technical expertise and on-the-spot support. Honestly, you can't just ship a robotic system and walk away; it requires a dedicated presence. This direct approach allows for detailed product demonstrations and personalized clinical education, which builds surgeon loyalty. While the direct model is the core, Zimmer Biomet also uses wholesale distributors to extend reach where a direct presence isn't as efficient, helping them penetrate new markets globally. The investment in this structure was noted, as higher costs due to investments in medical education events and sales efforts were a factor in Q1 2025 financial reporting. For instance, Q1 2025 net sales were $1.909 billion, showing the scale supported by these teams.

The company's focus on direct engagement supports its overall growth expectations, with full-year 2025 organic constant currency revenue growth guidance maintained between 3% to 5%.

Clinical education and training for surgeons on complex robotic systems.

Training is not optional; it's integrated into the relationship, especially for advanced tech like the ROSA® Robotics systems. Zimmer Biomet Holdings, Inc. runs numerous medical education courses designed to train surgeons on the safe and effective use of their products. These are typically 1 to 2-day events featuring didactic presentations, panel discussions, and, importantly, hands-on 'sawbones' demonstration sessions. You can see specific training events scheduled right through December 2025, covering everything from AI-Driven Precision in Hip Arthroplasty to ROSA® Robotics workshops. This continuous education is how they ensure product utilization aligns with their innovation pipeline, which includes plans for over 50 new product launches in 36 months. Having the internal sales force trained is a prerequisite for competing effectively.

The educational focus includes specialized tracks:

• ROSA® Robotics training sessions.
• Courses on the Persona® Revision Knee.
• Hip Arthroplasty precision workshops.
• Trauma Instructional Courses for Residents.

Long-term contracts with major hospital systems and Group Purchasing Organizations (GPOs).

Securing long-term agreements with major hospital systems and GPOs locks in volume and provides a stable revenue base. While specific contract dollar values aren't public in the latest filings, the strategic focus on institutional customers is clear. Zimmer Biomet Holdings, Inc. is actively expanding its footprint in the Ambulatory Surgery Center (ASC) market, which is a key area for contracting. By Q2 2025, the ASC segment accounted for over 20% of the company's U.S. sales, partly driven by the launch of ZBX™, their ASC-focused offering. These institutional relationships are vital for driving adoption of their entire portfolio, not just one product line. The company's ability to manage these large accounts directly impacts their ability to hit the raised full-year 2025 reported revenue guidance, which was lifted to a range of 6.7% to 7.7%.

Digital engagement via the You'll Be Back Campaign for patient resources.

Moving beyond the surgeon, Zimmer Biomet Holdings, Inc. has initiated a bold direct-to-patient strategy. CEO Ivan Tornos labeled the 'You'll Be Back' campaign, launched in February 2025 and featuring Arnold Schwarzenegger as Chief Movement Officer, as the boldest direct-to-patient program in the history of the organization. This initiative aims to motivate millions living with joint pain to seek treatment sooner. The campaign drives traffic to www.YoullBeBack.com, where patients can share their stories and access resources, including a 'Find a Doctor' tool. This digital push is a direct investment in demand generation, which, to be fair, was flagged as a factor pushing up spending over the first half of 2025. The goal is to create patient pull-through, complementing the direct sales force efforts with the surgeon.

Key elements of the digital patient outreach include:

• Featuring Chief Movement Officer Arnold Schwarzenegger.
• Online community for joint pain sufferers.
• A direct link to a tool for finding a qualified physician.
• Motivational content playing on classic film catchphrases.

Finance: review Q3 2025 marketing spend against patient acquisition cost estimates by next Tuesday.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Channels

You're looking at how Zimmer Biomet Holdings, Inc. gets its products-from hips to the new foot and ankle portfolio-into the hands of surgeons and into operating rooms globally as of late 2025. It's a mix of dedicated internal teams and external partners.

Direct sales force to hospitals and Ambulatory Surgery Centers (ASCs) globally.

The direct sales force is heavily focused on the U.S. market, which makes up about 62% of Zimmer Biomet Holdings, Inc.'s revenue, and around 50% of its profit. This team drives adoption of flagship products. For instance, U.S. Hips saw growth of 5.2% in the second quarter of 2025. A key metric here is competitive displacement; approximately 50% of U.S. Z1 Triple-Taper Femoral Hip System users are conversions from competitive accounts. International sales, which rely on a mix of direct and indirect channels, grew by 3.7% in the first quarter of 2025. Zimmer Biomet is defintely investing in specialized personnel to support data and digital technology solutions within this direct channel.

Third-party distributors, particularly in international and emerging markets.

Zimmer Biomet Holdings, Inc. supports its global reach through third-party networks. The company reports operations in over 25 countries and sales in over 100 countries. This structure is crucial for market penetration where a fully dedicated direct sales presence isn't feasible or cost-effective. The company acknowledges risks related to shifts in the regional sales mix handled by these distributors.

• Operations in 25+ countries.
• Sales presence in 100+ countries.
• Reliance on distributors for emerging market access.

ASC channel expansion, a key growth driver.

The shift of procedures to the Ambulatory Surgery Center (ASC) setting is a major focus area for channel strategy. This channel currently accounts for over 20% of Zimmer Biomet Holdings, Inc.'s U.S. sales. Management estimates that 40-60% of total knee orthopedics procedures could migrate to ASCs over the next three to five years. To capture this, Zimmer Biomet Holdings, Inc. is adding dedicated personnel focused on ASC strategy and reconstructive specialization.

Online platforms for patient engagement and product information.

Digital tools are integrated into the channel strategy to transform the patient experience and support providers. This includes the deployment of technologies leveraging data analytics and artificial intelligence, such as the OrthoGrid AI-driven surgical guidance system. While Zimmer Biomet Holdings, Inc.'s specific patient engagement platform metrics aren't public, the broader Patient Engagement Platforms Market is estimated to be valued at USD 31.0 billion in 2025.

• Leverage of integrated digital and robotic technologies.
• Use of AI for surgical guidance systems.
• Focus on data and data analytics to transform patient experience.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Customer Segments

The customer base for Zimmer Biomet Holdings, Inc. centers on the surgical community and the institutions that support them, with clear segmentation across procedure type and geography.

Orthopedic surgeons and surgical teams in hospitals and ASCs

Surgeons are the direct users whose adoption of new technology drives segment performance. The company's focus on new products and robotics directly targets this group.

• U.S. technology and data, bone cement and surgical sales increased by 20.3% in Q3 2025, driven by robotics capital sales.
• Persona OsseoTi, a knee implant component, represented nearly 30% of U.S. total knee implants as of Q3 2025.
• The company is the largest global knee and hip implant manufacturer, holding approximately 33% share in the knee market and 25% share in the hip market.
• In the patient-matched orthopedic guides market, Zimmer Biomet Holdings, Inc. holds a 30% global share.

Large hospital networks and Group Purchasing Organizations (GPOs)

These entities represent the institutional buyers that negotiate terms for the entire hospital system or network. Their purchasing power dictates broad product line adoption.

Patients requiring joint replacement (Knees, Hips) and extremity/trauma procedures

This segment is defined by the clinical need for Zimmer Biomet Holdings, Inc.'s core reconstructive and S.E.T. (sports medicine, extremities, and trauma) portfolios. The aging population is a key underlying driver for this entire customer base.

• Global Hips revenue grew 4% in Q2 2025.
• Sales in the unit selling sports medicine and trauma care products climbed 17.3% to $550.6 million in Q2 2025.
• The company expects to increase its global extremity market share to an estimated 10% position exiting 2025 following the Paragon 28 acquisition.
• The Total Knee Arthroplasty segment leads the patient-matched orthopedic guides market with a 42.9% share.

International healthcare providers, despite emerging market headwinds

International sales are a significant part of the business, though they have recently faced execution challenges that temper growth expectations compared to the U.S. market.

In 2024, Zimmer Biomet Holdings, Inc. generated 42% of its revenue from international markets, compared to 58% from the Americas.

• International Hip revenue grew by 2.7% in Q2 2025.
• Unexpected weakness in Eastern Europe, Latin America, and noncore S.E.T. segments impacted Q3 2025 growth by nearly 120 basis points.
• Full-year 2025 organic constant currency revenue growth guidance, excluding Paragon 28, was narrowed to a range of 3.5% to 4%, reflecting these international pressures.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Cost Structure

You're looking at the hard costs that drive Zimmer Biomet Holdings, Inc.'s operations as of late 2025. This structure is heavily weighted toward the physical creation of implants and the intellectual property that keeps their product line ahead.

The cost of goods sold (COGS) reflects the complexity of making high-precision orthopedic devices. For the third quarter ended September 30, 2025, the Cost of products sold, excluding intangible asset amortization was reported at \$559.3 million. This is a primary driver, given the specialized materials and stringent quality control required for implantable medical devices.

Beyond the direct cost of the product, you see significant non-production expenses. Selling, General, and Administrative (SG&A) expenses were substantial in Q3 2025, coming in at \$811.4 million. This expense line supports the global sales force necessary to get these complex products into operating rooms worldwide.

Investment in the future is also a major cost center. Research and development (R&D) for the third quarter of 2025 totaled \$115.9 million. This spending fuels the development pipeline, including robotics platforms and the next generation of implant materials, like the iodine-treated hip mentioned recently.

The company is actively managing its footprint and efficiency, which shows up in restructuring charges. The outline points to an estimated \$85.0 million pre-tax charge for the 2025 Restructuring Plan. For context, the 'Restructuring and other cost reduction initiatives' line item for Q3 2025 alone was \$21.4 million.

Trade headwinds present a variable cost pressure. While the outline suggests an impact of approximately $\$40$ million, recent guidance indicated a different scale. Zimmer Biomet expected the operating profit impact from tariffs for the full year 2025 to be in the range of \$60 million to \$80 million.

Here's a look at the key operating expense components from the third quarter of 2025, showing where the money is going:

To give you a sense of the overall operating leverage, the Operating Profit for the third quarter of 2025 was \$351.3 million. That profit was achieved against total reported operating expenses (including the items above and others) of \$1,650.1 million for the quarter.

The cost structure is also influenced by specific, non-recurring items:

• Estimated \$85.0 million pre-tax charge for the 2025 Restructuring Plan.
• Expected operating profit impact from tariffs for 2025 between \$60 million and \$80 million.
• The Q3 2025 statement also included a negative line item for Acquisition, integration, divestiture and related costs of (\$34.4 million), indicating costs associated with the recent Paragon 28 acquisition.

Finance: draft 13-week cash view by Friday.

Zimmer Biomet Holdings, Inc. (ZBH) - Canvas Business Model: Revenue Streams

You're looking at how Zimmer Biomet Holdings, Inc. (ZBH) actually brings in the money, which is pretty straightforward for a major medical device player. It's all about selling the hardware that helps surgeons fix joints and repair trauma. The revenue streams are heavily weighted toward their core reconstructive business, but the growth story is increasingly tied to their capital equipment and digital offerings, like the ROSA system.

For the second quarter of 2025, the product sales breakdown gives you a clear picture of where the volume is coming from. These are the big ticket items that drive the day-to-day cash flow:

The S.E.T. category, which covers Sports Medicine, Extremities, and Trauma, showed a strong jump, increasing 17.3% year over year in Q2 2025. That's definitely a segment management is leaning into, and it's a key part of their growth narrative.

Beyond the implants themselves, Zimmer Biomet Holdings, Inc. generates revenue from capital sales. This is where you see the upfront investment from hospitals and surgery centers for their advanced tools. This stream includes:

• Capital sales of robotic systems, such as the ROSA robotic-assisted surgery platform, where adoption is accelerating.
• Sales of other surgical equipment.
• Revenue tied to their integrated digital and robotic technologies that leverage data and AI.

The company is actively building out this capital/technology revenue stream, evidenced by the definitive agreement to acquire Monogram Technologies, an AI-driven robotics company, to expand their robotics suite. That move signals a strategic push to capture more of the high-value, recurring revenue potential that comes with advanced surgical systems.

Looking at the full picture for the year, management is projecting solid top-line performance. Zimmer Biomet Holdings, Inc. reaffirmed its full-year 2025 reported revenue growth guidance to be between 6.7% and 7.7% from the prior year. That's the target they are driving toward, balancing the steady implant business with the accelerating adoption of their newer technologies.

Here's a quick look at their overall guidance context as of late 2025:

Finance: draft 13-week cash view by Friday.